CAC
SRRA

Cowen and Company’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Cowen and Company’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,500
Closed -$39K – 639
2019
Q3 		$39K Buy
+2,500
New +$47.8K 0.01% 340

Other funds holding SRRA

NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
GT
Greenleaf Trust Kalamazoo, Michigan $10.4B AUM 0.97% 1-Year Est. Return

Cowen and Company's SRRA Position: Q4 2019 in Review

Cowen and Company sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q4 2019, closing a stake of 2,500 shares — an estimated $39K sold.

Cowen and Company first reported a position in SRRA in Q3 2019 and held it in 1 quarter. The position peaked at $39K in Q3 2019. 29 funds tracked by Wall St. Rank hold SRRA as of Q4 2019.

  • Cowen and Company reported no remaining Sierra Oncology, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Cowen and Company sold 2,500 Sierra Oncology, Inc. Common Stock shares in Q4 2019, an estimated $39K.
  • Cowen and Company first reported a position in Sierra Oncology, Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • Cowen and Company's Sierra Oncology, Inc. Common Stock position peaked at $39K in Q3 2019.
  • 29 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q4 2019.

Based on Cowen and Company's 13F filing for Q4 2019, filed 11 Feb 2020.